Interleukin-33 and Lower Tract Respiratory Diseases

Registration & Dinner @ 6:30 PM PT (Dinner provided.)

Prefer to participate online? Register for our livestream at ExchangeCME.com/IL33SanFranciscoVirtual

A MECC-Organized Symposium at the ATS 2025 International Conference. This evening symposia is open to all ATS 2024 International Conference attendees.

There is no fee to attend these educational programs; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Target Audience

This activity is designed to educate pulmonology, critical care medicine, infectious disease, and clinical immunology/allergy specialists who manage patients with severe viral lower respiratory tract disease, COPD, or other respiratory disorders. 

Program Overview

This live dinner symposium features expert panelists Dr. Jonathan M. Hand, Professor Dave Singh, and Professor Tom Wilkinson, who will explore the role of IL-33 in lower respiratory tract diseases and offer their insights on the latest advancements in treatment strategies that target its mechanisms. Agenda topics to be covered include the dual biologic function of IL-33 as both an inflammatory mediator and regulator of gene expression, IL-33 signaling pathways, implications of its dysregulation on the pathology of respiratory disease, rationale for targeting IL-33 for treatment development, and ongoing clinical investigations of biologic agents that inhibit IL-33. Interactive discussions and Q&A session will provide further opportunities for participant engagement and learning. Join us for this live and informative program!

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe IL-33 signaling and its pathophysiologic roles in COPD, severe viral lower respiratory tract disease, and other respiratory diseases
2. Discuss the mechanisms of action, clinical profiles, and published evidence for emerging biologic therapies targeting IL-33 for respiratory diseases
3. Incorporate emerging biologic therapies into practice for patients with COPD, severe viral lower respiratory tract disease, or other respiratory diseases as they become available

Program Agenda

6:30 pm    Registration & Dinner
7:00 pm    Preactivity Questionnaire and Faculty Introductions
7:10 pm    An Introduction to IL-33 Signaling
7:25 pm    IL-33 and Respiratory Diseases
7:50 pm    New Strategies to Target IL-33 Signaling in Respiratory Diseases
8:15 pm    Postactivity Questionnaire and Q&A Session

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.